AI Summary
✦ ClarthaJupiter Life Line Hospitals Limited is a multi-specialty hospital operator providing healthcare services under the Jupiter brand in India. Cardiology and cardiac surgery, oncology, and orthopedics, including robotic knee replacement, are key treatment platforms supporting revenue. Recent earnings beat analyst forecasts, while model upgrades and solid quarterly commentary point to continued 15.2% revenue growth. Profit increased only 0.4%, despite stable margins, indicating limited earnings conversion from top-line expansion. ROE is unavailable, while debt-to-equity of 37.84 means substantial leverage can amplify financial risk and distort shareholder returns. At 55.3 times earnings, the stock appears rich and trades at a premium to its modest profit growth. The open question is whether future hospital utilization and case mix can accelerate earnings enough to justify that valuation.
Price Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 6 analysts
Fundamentals
Fundamentals institutional score is 45 using growth durability 44.8.
Valuation
Valuation institutional score is 39 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 62 using mean target upside 8.5%; dispersion penalty 11.6; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 59 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 3 recent ticker-linked news items.
Signal Summary
Market intelligence remains Mixed. Available evidence provides partial support, while fundamentals and valuation remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 17.5% above historical median. Valuation is declining — currently in the strongly overvalued zone (z-score: +1.53). Confidence: 88%.
Live forward EPS implies next-12-month EPS of ₹8.18. Applying the stock's normalized valuation corridor produces a fair range of ₹355.42 to ₹422.17, with base value near ₹387.08 (+21.5% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹8.18
Forward P/E
39.0x
Base Fair Value
₹387.08
Fair Range
₹355.42 - ₹422.17
Upside To Base
+21.5%
Estimate Source
Live forward EPS
Growth Estimate
-13.3%
5Y Average
47.94
Current
55.62
Overvalued
51.61
Undervalued
43.45
5Y Average
27.81
Current
32.26
Overvalued
30.11
Undervalued
25.73
5Y Average
5.78
Current
6.71
Overvalued
6.65
Undervalued
4.91
Peers & Comparison
Sector: Health Care · Theme: Hospitals & Diagnostic Centres
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
RAINBOW CHILDRENS MED LTD RAINBOWHospitals & Diagnostic Centres | +33.2% | 15.7% | 54.4x Fair | -13% vs avg | +1.2% |
VIJAYA DIAGNOSTIC CEN LTD VIJAYAHospitals & Diagnostic Centres | +26.6% | 21.2% | 83.0x Premium | +33% vs avg | +28.0% |
PARK MEDI WORLD LIMITED PARKHOSPSHospitals & Diagnostic Centres | +19.3% | 16.1% | 45.7x Undervalued | -27% vs avg | +95.4% |
METROPOLIS HEALTHCARE LTD METROPOLISHospitals & Diagnostic Centres | +16.6% | 11.8% | 58.9x Fair | -6% vs avg | +7.6% |
THYROCARE TECH LTD THYROCAREHospitals & Diagnostic Centres | +24.3% | 20.1% | 54.8x Fair | -12% vs avg | +38.2% |
NARAYANA HRUDAYALAYA LTD. NHHospitals & Diagnostic Centres | +80.4% | 9.0% | 45.4x Undervalued | -27% vs avg | +6.8% |
GLOBAL HEALTH LIMITED MEDANTAHospitals & Diagnostic Centres | +26.5% | 11.9% | 71.4x Fair | +14% vs avg | +6.9% |
NEPHROCARE HEALTH SERV L NEPHROPLUSHospitals & Diagnostic Centres | +21.2% | 7.7% | 86.9x Premium | +39% vs avg | +48.1% |
JUPITER LIFE LINE HOSP L trades in line with peers (55.6x vs avg 62.6x), reflecting a fair valuation within the Hospitals & Diagnostic Centres cohort. Peers include RAINBOW CHILDRENS MED LTD, VIJAYA DIAGNOSTIC CEN LTD, PARK MEDI WORLD LIMITED — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹328 CrJun 2026Latest net profit
₹37 CrJun 2026Latest EPS
₹1.13Jun 2026Net margin
21.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 208 | 227 | 230 | 246 | 241 | 275 | 270 | 274 | 278 | 316 | 291 | 312 | 328 |
| Expenses + | 157 | 168 | 173 | 189 | 184 | 204 | 202 | 202 | 210 | 237 | 216 | 234 | 259 |
| Operating Profit | 51 | 59 | 57 | 57 | 57 | 71 | 69 | 72 | 68 | 79 | 76 | 78 | 69 |
| OPM % | 25% | 26% | 25% | 23% | 24% | 26% | 25% | 26% | 24% | 25% | 26% | 25% | 21% |
| Other Income + | 5 | 5 | 8 | 10 | 7 | 7 | 7 | 7 | 13 | 11 | 4 | 10 | 11 |
| Interest | 8 | 9 | 1 | 1 | 1 | 1 | 3 | 4 | 3 | 3 | 3 | 4 | 8 |
| Depreciation | 8 | 8 | 8 | 7 | 8 | 10 | 11 | 13 | 17 | 17 | 17 | 18 | 22 |
| Profit before tax | 41 | 48 | 56 | 59 | 55 | 67 | 62 | 62 | 61 | 70 | 60 | 66 | 50 |
| Tax % | 25% | 25% | 25% | 27% | 26% | 25% | 21% | 28% | 29% | 23% | 26% | 25% | 26% |
| Net Profit + | 30 | 36 | 42 | 43 | 41 | 50 | 49 | 44 | 43 | 55 | 44 | 49 | 37 |
| EPS in Rs | 1.08 | 1.10 | 1.29 | 1.32 | 1.24 | 1.53 | 1.50 | 1.36 | 1.32 | 1.67 | 1.35 | 1.50 | 1.13 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome